Amsterdam Molecular Therapeutics (in liquidation) Announces Publication Account
and Justification
Amsterdam, The Netherlands – September 12, 2012 – Amsterdam Molecular Therapeutics (AMT) Holding NV
in liquidation (in liquidatie) (Euronext: AMT) has been dissolved on April 5 2012. The account and justification
(rekening en verantwoording) has been prepared and is available for inspection from September 12, 2012
through November 7, 2012 at the Chamber of Commerce of Amsterdam (De Ruyterkade 5, Amsterdam) and at
the company's offices (Meibergdreef 61, Amsterdam Zuidoost). Absent any surplus following the final settlement
of the remaining assets and liabilities, no plan of distribution (plan van verdeling) shall be prepared. Delisting of
AMT shares from Euronext Amsterdam is expected to occur shortly after November 7, 2012.
Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidatie is per 5 april 2012 ontbonden. De rekening
en verantwoording is opgesteld en ligt van 12 september 2012 tot en met 7 november 2012 ter inzage ten
kantore van de Kamer van Koophandel Amsterdam (De Ruyterkade 5, Amsterdam) en ten kantore van de
rechtspersoon (Meibergdreef 61, Amsterdam Zuidoost). Omdat er na finale afwikkeling van de resterende activa
en verplichtingen geen batig saldo resteert, zal geen plan van verdeling worden opgesteld. De notering van AMT
aandelen aan Euronext wordt geacht te eindigen kort na 7 november 2012.
About Amsterdam Molecular Therapeutics (in liquidation)
On March 30, 2012, an extraordinary general meeting of shareholders approved a major corporate restructuring
and financing transaction involving the disposal of the Group’s entire business and operations to uniQure B.V.
and the subsequent dissolution, liquidation and delisting of AMT (in liquidation).
Immediately following the completion of the disposal, the dissolution of the company as resolved by the EGM
became effective on April 5, 2012, with Mr. Jörn Aldag and Mr. Piers Morgan being the liquidators that shall
liquidate the company's dissolved property.
AMT (in liquidation) and the AMT shares will continue to exist until the liquidation is finalised, which is expected
to occur in November 2012. AMT (in liquidation) and its shares ceasing to exist upon the ending of the liquidation
shall effectively also result in the delisting of AMT (in liquidation), to the extent the delisting cannot be achieved
at an earlier date in consultation with Euronext Amsterdam and subject to such conditions as Euronext
Amsterdam may propose.
Further information on AMT (in liquidation), can be found on AMT (in liquidation)’s website
www.amtbiopharma.com.
For further enquiries:
Jörn Aldag
Liquidator
AMT (in liquidation)
Tel : +31 20 566 8014
[email protected]
Certain statements in this press release are “forward-looking statements” including those that refer to
management's plans and expectations for future operations, prospects and financial condition. Words such as
“strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,”
“goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements.
Such statements are based on current expectations only. Undue reliance should not be placed on these
statements because, by their nature, they are subject to known and unknown risks and can be affected by
factors that are beyond the control of AMT (in liquidation). Actual results could differ materially from current
expectations due to a number of factors and uncertainties. AMT (in liquidation) expressly disclaims any intent or
obligation to update any forward-looking statements herein except as required by law.